Notably, a priori inflammation-stratified designs and secondary analyses suggest that baseline CRP and related markers moderate antidepressant response to n-3 PUFAs, consistent with a “inflamed depression” subtype more likely to benefit [51]. Here, CRP is linked to major depressive disorder.